T-cell receptor


Also found in: Dictionary, Thesaurus, Medical, Acronyms, Wikipedia.

T-cell receptor

[′tē ‚sel ri‚sep·tər]
(immunology)
Protein on the surface of T lymphocytes that specifically recognizes molecules of the major histocompatibility complex, either alone or in association with foreign antigens. Abbreviated TCR.
References in periodicals archive ?
"We hope that these experiments will provide the information we need to safely improve these T-cell receptors to target cancer and other types of human diseases," Dr Cole said.
Eureka's lead asset, ET140202, utilizes Eureka's proprietary ARTEMIS T-cell receptor platform engineered with a proprietary human TCR-mimic antibody to target an AFP-peptide/HLA-A2 complex on HCC cancer cells.
The strategy for newborn SCIDS screening is based upon polymerase chain reaction quantification of T-cell receptor excision circles (TRECs)--small circles of DNA created in T-cells during their passage through the thymus--from dried blood spots (DBS) on newborn screening cards.
In the cytoplasm, DEX can bind to and interfere with regulatory factors, disrupt the T-cell receptor (TCR) complex, and impair T-cell signaling (Lowenberg et al.
Because there are 2 case reports of CD3 deficiency causing T-cell immunodeficiency (7, 8) and CD3 is part of the T-cell receptor complex on mature T cells, it was surmised that CD3 could be used as a marker for the presence or absence of T cells (9).
Technology developed by Immunocore has refined T-cell receptors so that they can be used as drugs that seek out and destroy abnormal or infected cells.
REGN1979 is an investigational bispecific monoclonal antibody and is designed to trigger tumor killing by binding to both a B-cell tumor protein and an immune system T-cell receptor. "We are very encouraged by the continued high response rates observed with REGN1979 in both relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma, cancers with typically poor outcomes," said Israel Lowy, M.D., Ph.D., Senior Vice President and Head of Clinical and Translational Sciences, Oncology at Regeneron.
The facility will manufacture various investigational T-cell receptor (TCR) therapies, including the commercially available personalised cancer treatment Yescarta (axicabtagene ciloleucel).
ET140202 utilizes Eureka's proprietary ARTEMIS T-cell receptor platform engineered with a proprietary human TCR-mimic antibody to target an AFP-peptide/HLA-A2 complex on HCC cancer cells.
will develop both autologous and allogenic ACT approaches by capitalizing on MD Anderson's world-leading clinical oncology and cell therapy expertise and Immatics' unrivaled cancer target and T-cell receptor (TCR) discovery capabilities.
Most cases are of [gamma]/[delta] T-cell origin, with a few expressing [alpha]/[beta] T-cell receptor. Hepatosplenic T-cell lymphoma exhibits a rapidly progressive clinical course and a poor response to currently available therapies, with a 5-year overall survival rate of 7%.
Immunocore will conduct a Phase Ib/II trial combining Medlmmune's investigational checkpoint inhibitors MEDI4736 (anti-PD-L1) and/or tremelimumab (antiCTLA-4) with IMCgp100, its lead T-cell receptor, for the potential treatment of patients with metastatic melanoma.

Full browser ?